Citations

Clear

431 citation(s) found for "Schmidt, B".

Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States
Hawley, Jessica E. , Sun, Tianyi , Chism, David D. , Duma, Narjust , Fu, Julie , Gatson, Na Tosha , Mishra, Sanjay , Nguyen, Ryan H., Reid, Sonya , Serrano, Oscar K. , Singh, Sunny , Venepalli, Neeta K. , Bakouny, Ziad , Bilen, Mehmet Asım , Choueiri, Toni K. , Dawsey, Scott J. , Fecher, Leslie A. , Flora, Daniel , Friese, Christopher R. , Glover, Michael , Gonzalez, Cyndi J, Goyal, Sharad , Khan, Hina, Lewis, Mark A. , McKay, Rana R. , Messing, Ian , Puc, Matthew , Ravindranathan, Deepak , Rhodes, Terence D., Rivera, Andrea Verghese, Roller, John , Shah, Sumit , Shaya, Justin , Streckfuss, Mitrianna, Wulff‐Burchfield, Elizabeth , Xie, Zhuoer , Shah, Dimpy P. , French, Benjamin , Verma, Amit , Gartrell, Benjamin A. , Ohri, Nitin , Butt, Omar H. , Campian, Jian , Fiala, Mark A. , Monahan, Ryan, Bohachek, Pamela, Mundt, Daniel , Tadesse, Eyob, Lammers, Philip E. , Prete, Salvatore A. Del , Bär, Michael , Gulati, Anthony P., Lo, K. M. Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Nakayama, John , Gupta, Shilpa , Ahluwalia, Manmeet S. , Lemmon, Christopher A. , Nizam, Amanda , Hoppenot, Claire , Bouchard, Gabrielle, Busser, Fiona, Connors, Jean M. , Curran, Catherine , Demetri, George D., Kelleher, Kaitlin M. , Shaw, Grace, Allen, Eli Van, Nuzzo, Pier Vitale , Zon, Rebecca L. , Zhang, Tian , Leighton, John, Grivas, Petros , Lynch, Ryan C. , Schweizer, Michael T. , Vinayak, Shaveta , Wagner, Michael J. , Clément, Jessica , Daher, Ahmad , Dailey, Mark, Jayaraj, Asha, Hsu, Emily , Menendez, Alvaro G. , Rathmann, Joerg, Accordino, Melissa , Alexander, Mariam P., Mushtaq, Sarah, Bernicker, Eric , Deeken, John F. , Shafer, Danielle , Gill, David , Low, Clarke A., Mashru, Sandeep H., Mansoor, Abdul-Hai, Zaren, Howard A. , Smith, Stephanie J., Akhtari, Mojtaba, Lau, Eric , Reeves, Mark E. , Elms, Destry, Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Kulkarni, Amit , Shah, Surbhi , Rosovsky, Rachel , Reynolds, Kerry L. , Bardia, Aditya , Gainor, Justin F. , Zubiri, Leyre , Bonnen, Mark , Mahadevan, Daruka , Salazar, Mary, Faller, Bryan A. , Ajmera, Archana , Brouha, Sharon S. , Cabal, Angelo , Kligerman, Seth , Weissmann, Lisa B., Jani, Chinmay , Thomson, Carey C. , Knoble, Jeanna, Glace, Mary Grace, Stauffer, Karen, Zacks, Rosemary, Blau, Sibel , Menon, Harry, Rovito, Marc A., Elshoury, Amro, Misdary, Christian, Shah, Mansi , Mahmood, Sana , Mico, Vasil, Logan, Barbara, Mandapakala, Chaitanya, Cabebe, Elwyn C., Jha, Alokkumar , Schapira, Lidia , Wu, Julie , Subbiah, Suki , Lopes, Gilberto , Revankar, Sanjay G. , Addison, Daniel , Chen, James L. , Karivedu, Vidhya , Lustberg, Maryam B. , Wall, Sarah , Williams, Nicole , Kasi, Anup , Edwin, Natasha, Smits, Melissa, Owenby, Susie, Doroshow, Deborah B. , Galsky, Matthew D. , Zhu, Huili , Sueyoshi, Mark, Riess, Jonathan W. , Patel, Kanishka G. , Rubinstein, Samuel M. , Ahmad, Syed A. , Grover, Punita , Kharofa, Jordan , Marcum, Michelle, Park, Cathleen, Geiger, Christoper L., Bishnoi, Rohit , Russ, Atlantis Dawn, Rho, Young Soo , Feldman, Lawrence , Hoskins, Kent , Gantt, Gerald, Liu, Li , Khan, Mahir, Nguyen, Ryan H., Schwartz, Candice, Mavromatis, Blanche H., Bijjula, Ragneel R., Cheng, Alex , Duda, Stephany N. , Enriquez, Kyle T. , Gillaspie, Erin A. , Hennessy, Cassandra , Johnson, Douglas B. , Slosky, David, Solórzano, Carmen C. , Vega-Luna, Karen, Kennecke, Hagen F. , Schroeder, Brett A., Carducci, Theresa M., Goldsmith, Karen J., Loon, Susan Van, Topaloĝlu, Ümit , Alimohamed, Saif, Rice, Robert, Cabalona, Wilhelmina D., Pilar, Christine, Peddi, Prakash , Rosen, L, McCollough, Briana Barrow, LoRusso, Patricia , Masters, Tyler, Choueiri, Toni K , Bakouny, Ziad , Hawley, Jessica E , Mishra, Sanjay , Wu, Julie T , Xie, Zhuoer , Zubiri, Leyre , Gatson, Na Tosha N , Fiala, Mark A , Ahluwalia, Manmeet S , Lustberg, Maryam , Nguyen, Ryan H., Bashir, Babar , Caimi, Paolo F. , Hálfdánarson, Þorvarður R. , Hershman, Dawn L. , Labaki, Chris , Pennell, Nathan A , Schwartz, Gary K. , Thompson, Michael A. , Yu, Peter Paul , Warner, Jeremy L. , Hwang, Clara , Halmos, Balázs , Goel, Sanjay , Sica, Roberto Alejandro , Thakkar, Astha , Stockerl‐Goldstein, Keith , Henderson, Jeffrey P. , Zhou, Alice Y. , Panagiotou, Orestis A. , Egan, Pamela , Farmakiotis, Dimitrios , Olszewski, Adam J. , Loaiza‐Bonilla, Arturo , Bar, Michael H., Rose, Suzanne J. , Barnholtz‐Sloan, Jill S. , Li, Ang , Giordano, Antonio , Nohria, Anju , Schmidt, Andrew , Xu, Vincent Eric , Halabi, Susan , Lyman, Gary H , Graber, Jerome J. , Khaki, Ali Raza , Loggers, Elizabeth T , Nakasone, Elizabeth S. , Tachiki, Lisa , Yeh, Albert C. , Huynh‐Le, Minh‐Phuong , Rosenstein, Lori J. , Dailey, Mark, Elias, Rawad , Gadgeel, Shirish M. , Bhutani, Divaya , Reuben, Daniel Y. , Alexander, Mariam, Nagaraj, Gayathri , Berg, Stephanie , Morgans, Alicia K. , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Sachs, Zohar , Boland, Genevieve M. , Bekaii‐Saab, Tanios , Desai, Aakash , Mesa, Ruben A. , Ramirez, Amelie G , Shah, Pankil , Hsiao, Albert , Rink, Cameron L. , Joshi, Monika , Griffiths, Elizabeth A. , Jabbour, Salma K , McNair, Christopher M. , Kloecker, Goetz Hans , Stover, Daniel G. , Gatti-Mays, Margaret Elena , Jhawar, Sachin R. , Palmer, Joshua D. , Wotman, Michael T. , Fazio, Alyson, Huber, Kathryn E. , Wood, William A. , Jensen, Christopher Edward , Kumar, Vaibhav , Wise-Draper, Trisha Michel , Gulati, Shuchi , Latif, Tahir , Shaikh, Hira , Bowles, Daniel W. , Markham, Merry Jennifer , Shah, Chintan , Acoba, Jared David , Nguyen, Ryan H., Pasquinelli, Mary M. , Vikas, Praveen , Zaman, Qamar U., Davis, Elizabeth J. , Hausrath, Daniel J. , Hsu, Chih–Yuan , Li, Xuanyi , Rini, Brian I. , Shyr, Yu , Tucker, Matthew D. , Wang, Lucy Lu , Aboulafia, David M. , Schroeder, Brett , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine

Mayo Clinic

JAMA Network Open | January 4, 2022 | Volume: 5 | Issue: 1 | Pages: e2142046

10.1001/jamanetworkopen.2021.42046 | PMID 34982158 Get It

Gene-mapping study of extremes of cerebral small vessel disease reveals TRIM47 as a strong candidate
Mishra, Aniket , Duplàa, Cécile , Suzuki, Hideaki , Li, Shuo , Bartz, Traci M. , Jian, Xueqiu , Zhao, Wei , Hofer, Edith , Wittfeld, Katharina , Bis, Joshua C, Adams, Hieab H.H. , Satizábal, Claudia L. , Gottesman, Rebecca F., Gampawar, Piyush , Weiß, Stefan , Yu, Miao , Lopez, Oscar L., Vernooij, Meike W. , Soumaré, Aïcha , Smith, Jennifer A. , Zhu, Yi‐Cheng , Rotter, Jerome I. , Dufouil, Carole , Maniega, Susana Muñoz , Lathrop, Mark, Boerwinkle, Erik, Schmidt, Reinhold, Ihara, Masafumi , Joutel, Anne , Tournier‐Lasserve, Elisabeth , Mosley, Thomas H. , DeCarli, Charles , Tzourio, Christophe , Kardia, Sharon L. R., Teumer, Alexander , Schmidt, Helena , Wardlaw, Joanna M. , Fornage, Myriam , Guðnason, Vilmundur , Longstreth, W.T. , Couffinhal, Thierry , Debette, Stéphanie , Zhao, Wei , Sargurupremraj, Muralidharan , DeCarli, Charles , Suzuki, Hideaki , Sargurupremraj, Muralidharan , Bülow, Robin , Weiss, Stefan , Völker, Uwe , Smith, Jennifer A , Yang, Qiong , Amouyel, Philippe , Tzourio, Christophe , Teumer, Alexander , van Duijn, Cornelia M , Matthews, Paul M , Debette, Stephanie , Wardlaw, Joanna Marguerite , Adams, Hieab H H , Satizabal, Claudia L , Rotter, Jerome I , Vojinović, Dina , Zilhäo, Nuno R. , Harris, Sarah , Auwera, Sandra Van der , Luciano, Michelle , Bis, Joshua C, Bastin, Mark E. , Beiser, Alexa , Völker, Uwe , Kacprowski, Tim , Knopman, David S. , Morris, Zoë , Hernández, Maria del Carmen Valdés , Mazoyer, Bernard , Launer, Lenore J. , Deary, Ian J. , Amouyel, Philippe , Psaty, Bruce M. , Grabe, Hans Jörgen , Duijn, Cornelia M. van , Ikram, M. Arfan , Seshadri, Sudha , Matthews, Paul M.

Mayo Clinic

Brain | December 8, 2021 | Volume: 145 | Issue: 6 | Pages: 1992-2007

10.1093/brain/awab432 | PMID 35511193 Get It

Abstract Cerebral small vessel disease is a leading cause of stroke and a major contributor to cognitive decline and dementia, but our understanding of specific genes underlying the cause of sporadic cerebral small vessel disease is limited. We report a genome-wide association study and a whole-exome association study on a composite extreme phenotype of cerebral small vessel disease derived from its most common MRI features: white matter hyperintensities and lacunes. Seventeen population-based cohorts of older persons with MRI measurements and genome-wide genotyping (n = 41 326), whole-exome sequencing (n = 15 965), or exome chip (n = 5249) data contributed 13 776 and 7079 extreme small vessel disease samples for the genome-wide association study and whole-exome association study, respectively. The genome-wide association study identified significant association of common variants in 11 loci with extreme small vessel disease, of which the chr12q24.11 locus was not previously reported to be associated with any MRI marker of cerebral small vessel disease. The whole-exome association study identified significant associations of extreme small vessel disease with common variants in the 5′ UTR region of EFEMP1 (chr2p16.1) and one probably damaging common missense variant in TRIM47 (chr17q25.1). Mendelian randomization supports the causal association of extensive small vessel disease severity with increased risk of stroke and Alzheimer’s disease. Combined evidence from summary-based Mendelian randomization studies and profiling of human loss-of-function allele carriers showed an inverse relation between TRIM47 expression in the brain and blood vessels and extensive small vessel disease severity. We observed significant enrichment of Trim47 in isolated brain vessel preparations compared to total brain fraction in mice, in line with the literature showing Trim47 enrichment in brain endothelial cells at single cell level. Functional evaluation of TRIM47 by small interfering RNAs-mediated knockdown in human brain endothelial cells showed increased endothelial permeability, an important hallmark of cerebral small vessel disease pathology. Overall, our comprehensive gene-mapping study and preliminary functional evaluation suggests a putative role of TRIM47 in the pathophysiology of cerebral small vessel disease, making it an important candidate for extensive in vivo explorations and future translational work.
Shared Decision Making in Cardiac Electrophysiology Procedures and Arrhythmia Management
Chung, Mina K. , Fagerlin, Angela , Wang, Paul J. , Ajayi, Tinuola B. , Allen, Larry A. , Baykaner, Tina , Benjamin, Emelia J. , Branda, Megan E. , Cavanaugh, Kerri L. , Delaney, Rebecca K. , Eckhardt, Lee L. , Hargraves, Ian , Hills, Mellanie True , Kalscheur, Matthew M. , Kramer, Daniel B. , Kunneman, Marleen , Lampert, Rachel , Lewis, Krystina B. , Lü, Ying , Matlock, Daniel D. , McCarthy, Sarah , Orland, Kate M. , Pundi, Krishna , Roden, Dan M. , Saarel, Elizabeth V. , Schmidt, Monika M. , Sears, Samuel F. , Stafford, Randall S. , Wass, Sojin Y. , Wright, Jennifer M. , McCarthy, Sarah R. , Branda, Megan , Chen, Lin Y , Delaney, Rebecca K , Eckhardt, Lee L , Grady, Kathleen L , Hargraves, Ian G, True Hills, Mellanie , Kalscheur, Matthew M , Kramer, Daniel B , Kunneman, Marleen , Lampert, Rachel , Langford, Aisha T , Lewis, Krystina B , Lu, Ying , Mandrola, John M , Martinez, Kathryn , Matlock, Daniel D , McCarthy, Sarah R , Montori, Victor M , Noseworthy, Peter A , Orland, Kate M , Ozanne, Elissa M , Passman, Rod , Pundi, Krishna , Roden, Dan M. , Saarel, Elizabeth V , Schmidt, Monika M , Sears, Samuel F , Stacey, Dawn , Stafford, Randall S , Steinberg, Benjamin A , Youn Wass, Sojin , Wright, Jennifer M , Cavanaugh, Kerri , Benjamin, Emelia J , Fagerlin, Angela , Chen, Lin Y. , Crossley, George , Martinez, Kathryn A. , Montori, Víctor M. , Noseworthy, Peter A. , Ozanne, Elissa M. , Passman, Rod , Stacey, Dawn , Steinberg, Benjamin A. , McCarthy, Sarah R.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | December 6, 2021 | Volume: 14 | Issue: 12 | Pages: No page available

10.1161/circep.121.007958 | PMID 34865518 Get It

Shared decision making (SDM) has been advocated to improve patient care, patient decision acceptance, patient-provider communication, patient motivation, adherence, and patient reported outcomes. Documentation of SDM is endorsed in several society guidelines and is a condition of reimbursement for selected cardiovascular and cardiac arrhythmia procedures. However, many clinicians argue that SDM already occurs with clinical encounter discussions or the process of obtaining informed consent and note the additional imposed workload of using and documenting decision aids without validated tools or evidence that they improve clinical outcomes. In reality, SDM is a process and can be done without decision tools, although the process may be variable. Also, SDM advocates counter that the low-risk process of SDM need not be held to the high bar of demonstrating clinical benefit and that increasing the quality of decision making should be sufficient. Our review leverages a multidisciplinary group of experts in cardiology, cardiac electrophysiology, epidemiology, and SDM, as well as a patient advocate. Our goal is to examine and assess SDM methodology, tools, and available evidence on outcomes in patients with heart rhythm disorders to help determine the value of SDM, assess its possible impact on electrophysiological procedures and cardiac arrhythmia management, better inform regulatory requirements, and identify gaps in knowledge and future needs.
Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors
Mody, Kabir , Kelley, Robin Katie, Sahai, Vaibhav , Schmidt‐Kittler, Oleg , Shen, Jinshan , Jen, Kai Yu , Deary, Alicia, Padval, Mahesh V. , Sherwin, Cori Ann , Ferté, Charles , Wolf, Beni B. , Sahai, Vaibhav , Goyal, Lipika , Borad, Mitesh J. , Subbiah, Vivek , Mahipal, Amit , Kamath, Suneel Deepak , Kelley, Robin Kate , Kim, Richard D. , El-Khoueiry, Anthony B. , Dotan, Efrat , Guo, Wei, Schram, Alison M.

Mayo Clinic

Molecular Cancer Therapeutics | December 3, 2021 | Volume: 20 | Issue: 12_Supplement | Pages: P02-02-P02-02

10.1158/1535-7163.targ-21-p02-02 Get It

Abstract INTRODUCTION: Oncogenic FGFR2 alterations (fusions/rearrangements, amplifications, mutations) are key drivers in cholangiocarcinoma (CCA) and multiple solid tumors. Current pan-FGFR inhibitor (FGFRi) therapy is limited by off-isoform toxicity and acquired FGFR2 kinase domain resistance mutations. RLY-4008 is a highly selective and potent oral inhibitor designed to target both FGFR2 driver and resistance mutations. We initiated a first-in-human study in advanced solid tumors patients (pts) to define the safety, pharmacokinetics (PK) and efficacy of RLY-4008 (NCT04526106). METHODS: Adult pts received RLY-4008 QD or BID on a 4-week cycle following a BOIN escalation design. Adverse events (AEs), PK, ctDNA and anti-tumor activity (RECIST 1.1) were assessed. RESULTS: As of 16AUG21, 45 pts (35 CCA; 10 other) have been treated with RLY-4008 at total daily doses of 30-200 mg (18 pts BID; 27 pts QD). 44 pts had oncogenic FGFR2 alterations (26 fusions/13 mutations/5 amplifications). The median number of prior anti-neoplastic therapies was 3 (range 1-15). 94% (33/35) of CCA pts had prior chemotherapy and 69% (24/35) had prior FGFRi. 56% (9/16) CCA pts with prior FGFRi and evaluable ctDNA had ≥1 FGFR2 resistance mutation at baseline, most commonly at positions 549 (8/9), 617 (3/9), or 564 (2/9). RLY-4008 had rapid absorption (Tmax 1-7h), half-life to support QD dosing (18-34 h), dose-dependent exposure (AUC; Cmax) and predicted FGFR2 occupancy >85% across dose levels. The MTD has not been defined, and QD dose exploration continues to select the optimal biologically efficacious dose. AEs occurring in >20% of pts include stomatitis (49%), palmar-plantar erythrodysesthesia (PPE, 38%), dry mouth (29%), and nail toxicities (22%), majority of which were ≤Gr 2. 6 pts had Gr 1-2 retinopathy, which resolved in all cases. 5 AEs were considered dose limiting toxicities: 4 in BID (rash/PPE/mucositis/hyperbilirubinemia) and 1 in QD (retinopathy). No Gr 4/5 drug-related AEs were seen. 25 pts remain on treatment (range 1-37 weeks). RLY-4008 showed broad anti-tumor activity across dose levels and FGFR2 alterations with radiographic tumor reductions of ≥10% in 59% pts (19/32; -11% to -83%). Activity was seen in FGFRi-naïve, FGFR2-fusion+ CCA with PRs in 50% of pts (3/6, 2 confirmed and 1 pending confirmation; -56% to -83%). Activity was also seen in FGFRi pre-treated FGFR2-fusion+ CCA pts (N=16) with 16 SD, including 9 pts with tumor reduction ≥10% (from -12% to -35%). Of the FGFRi pre-treated FGFR2-fusion+ CCA patients with detectable FGFR2 resistance mutations in ctDNA at baseline, 78% (7/9) were undetectable at C2D1. CONCLUSION: RLY-4008 demonstrates promising safety, tolerability, and clinical activity in FGFR2-altered solid tumor pts, including those who progressed on prior FGFRi therapy. Consistent with the FGFR2-selective mechanism, minimal off-isoform toxicity (FGFR1-hyperphosphatemia; FGFR4-diarrhea) was seen. These encouraging data validate selective targeting of FGFR2 and suggest that RLY-4008 has potential to overcome resistance to FGFRi. Citation Format: Lipika Goyal, Mitesh Borad, Vivek Subbiah, Amit Mahipal, Suneel Kamath, Kabir Mody, Robin Katie Kelley, Richard Kim, Vaibhav Sahai, Anthony El-Khoueiry, Efrat Dotan, Oleg Schmidt-Kittler, Jinshan Shen, Kai Yu Jen, Alicia Deary, Wei Guo, Mahesh Padval, Cori Ann J. Sherwin, Charles Ferte, Beni Wolf, Alison M. Schram. First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P02-02.
Multi-institution Assessment of the Accuracy of Cardiac Computed Tomography in Preparation for Superior Cavopulmonary Connection
Nunes, Mariana De Oliveira , Overman, David M. , Casey, Susan A. , Witt, Dawn , Schmidt, Christian , Griffin, Lindsay , Witt, Dawn R , Schmidt, Christian W , Han, B Kelly, Rigsby, Cynthia K. , Han, Bo

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | November 30, 2021 | Volume: 12 | Issue: 6 | Pages: 700-705

10.1177/21501351211035685 | PMID 34846969 Get It

Background Patients with single ventricle (SV) congenital heart disease (CHD) undergo several interventions in the first years of life. Advanced diagnostics are required for interstage assessment of anatomy, but are associated with significant diagnostic risk. We sought to evaluate image quality, risk, and accuracy of cardiac computed tomography (CCT) for evaluation of anatomy prior to superior cavopulmonary connection (SCPC) compared to surgical findings across 2 institutions. Methods A retrospective evaluation of image quality, risk, and accuracy of pre-SCPC CCT was performed at 2 institutions between January 1, 2010 and September 30, 2016. Results CCT was performed in 90 SV CHD patients with a median age of 4.03 months (interquartile range [IQR] 3.36, 5.33) prior to SCPC. Image quality was optimal (84%) or good (16%) in all patients, without significant discrepancy compared to surgical findings. 7 patients (8%) required interventional cardiac catheterization subsequent to CCT and before surgical intervention. 49% of scans were performed without sedation, 43% of scans were performed with mild to moderate sedation, and 8% of scans were performed with general anesthesia. The median total procedural dose-length product (DLP) was 18 (IQR 14, 26) mGy*cm, estimating an age adjusted radiation dose of 1.4 millisievert (mSv). One minor (1%) adverse event was reported within 24 h of the CCT. Surgical complications were unrelated to the presurgical findings. Conclusions CCT for pre-SCPC evaluation is safe, with excellent accuracy for anatomy at the time of surgical intervention across 2 institutions. In select patients, noninvasive evaluation with CCT may be indicated.
A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)
Harrington, Alexandra M., Michaelis, Laura C. , Abedin, Sameem , Carlson, Karen, Runaas, Lyndsey, Longo, Walter, Hinman, Alexander, Maldonado-Schmidt, Sonia, Thomas, Althea, Baim, Arielle , Litzow, Mark R. , Abedin, Sameem , Murthy, Guru Subramanian Guru , Kaufmann, Scott H. , Szabó, Anikó , Atallah, Ehab

Mayo Clinic

Blood | November 24, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 2347-2347

10.1182/blood-2021-149351 Get It

Abstract Background: Outcomes of patients with relapsed/refractory AML (RR-AML) have remained poor. Therapy with venetoclax based combinations in this setting leads to CR/CRi rates of 21-49% (DiNardo CD et al. Am J Hematol 2018, Aldoss I et al. Haematologica 2018, Stahl M et al. Blood Adv 2020). Preclinical studies with BCL-2 inhibitors indicate potential mechanisms of drug resistance including overexpression of the anti-apoptotic protein MCL-1 (Konopleva et al. Cancer Cell. 2006). Pevonedistat is a first in class inhibitor of Nedd8 activating enzyme that induces the pro-apoptotic protein NOXA leading to neutralization of MCL-1 and apoptosis. Preclinical studies evaluating the combination of pevonedistat and venetoclax against AML cell lines have demonstrated a synergistic effect (Knorr KL et al. Cell Death Differ. 2015). Hence, we designed a phase I study to assess the safety and tolerability of adding pevonedistat to the combination of azacitidine and venetoclax in patients with RR-AML. Study design and methods: We conducted a phase I study with the combination of pevonedistat, venetoclax and azacitidine in patients with RR-AML. Patients aged 18 years or above with morphologically documented RR-AML, ECOG performance status 0-2 and adequate organ function were eligible. Major exclusion criteria were isolated extramedullary relapse, hematopoietic cell transplantation (HCT) within 100 days of enrollment, and active acute GVHD. Previous therapy with hypomethylating agents (HMA) or venetoclax was not an exclusion criterion. The dose escalation phase was conducted using 3+3 design. Treatment included azacitidine (75 mg/m 2 daily x 7 days), venetoclax (400 mg daily x 28 days), and pevonedistat in escalating doses (10-20 mg/m 2 IV days 1,3,5 of each cycle) with a cycle length of 28 days. Pevonedistat was given at 10 mg/m 2 dose in cohort 1, 15 mg/m 2 dose in cohort 2 and 20 mg/m 2 dose in cohort 3. The primary endpoint is to determine the recommended phase 2 dose (RP2D) and toxicity profile of pevonedistat, azacitidine and venetoclax. Other endpoints included determination of response rates, duration of response, survival, pharmacokinetics, correlation of response rates with AML genomic profile, correlation of pretreatment levels of BCL2, BCLXL, MCL1, BAX or BAK with response, determination of changes in NOXA (PMAIP1) mRNA and protein expression pre-and post-pevonedistat treatment, evaluation of BH3 mimetic profiling on bone marrow samples by flow cytometry and assessing the sensitivity of leukemia and leukemic stem/progenitor cells to pevonedistat ex vivo. Results: Thirteen patients participated in the dose escalation phase, 12 of whom were evaluable. Median age was 69 years (61-91), 30.8% had secondary/therapy related AML, 69.2% with adverse risk disease, 53.8% previously received venetoclax/HMA and 23.1% had relapse after prior allogeneic hematopoietic cell transplantation (HCT) (Table 1). Seven patients were enrolled into cohort 1 (pevonedistat 10 mg/m 2 dose) of which one was not evaluable, three patients enrolled into cohort 2 (pevonedistat 15 mg/m 2 dose), and three patients enrolled into cohort 3 (pevonedistat 20 mg/m 2 dose). Grade 3 or higher AEs included febrile neutropenia (23%), infection (15%), anemia (38%), neutropenia (54%), thrombocytopenia (38%). There was 1 dose limiting toxicity (DLT) in cohort 1 (atrial fibrillation) that triggered cohort expansion. However, subsequent patients did not experience DLT despite planned dose escalation. Of the 12 evaluable total patients, CR/CRi was observed in 5 (41.6%) patients. Notably, patients with RR-AML who were venetoclax/HMA naïve had a CR/CRi 83.3% (5/6 patients). The response rates for each cohort are summarized in Table 2. Three of the five patients with CR/CRi (60%) achieved MRD negativity by flow cytometry. Four patients who achieved CR/CRi proceeded to allogeneic HCT after therapy. Median OS of the cohort was 5.4 months (1.8-14) and median OS was not reached in patients with CR/CRi. Conclusions: The addition of pevonedistat to venetoclax and azacitidine backbone is safe and well tolerated in patients with RR-AML. Dose escalation yielded encouraging efficacy in venetoclax/HMA naïve RR-AML patients. The study is currently in the dose expansion phase. Details on correlative studies examining mechanisms of therapeutic efficacy and resistance will be reported in the main meeting. Figure 1 Figure 1. Disclosures Guru Murthy: Cardinal health: Honoraria; TG Therapeutics: Other: Advisory board meeting; DAVA Oncology: Honoraria; CancerExpertNow: Honoraria; Qessential: Honoraria; Techspert: Consultancy; Curio Sciences: Honoraria; Guidepoint: Consultancy. Abedin: AltruBio: Research Funding; Helsinn: Research Funding; Amgen: Honoraria; Pfizer: Research Funding; Agios: Honoraria; Actinium: Research Funding; Astellas Pharma Inc.: Research Funding. Litzow: Jazz: Other: Advisory Board; Pluristem: Research Funding; Actinium: Research Funding; Amgen: Research Funding; Astellas: Research Funding; AbbVie: Research Funding; Omeros: Other: Advisory Board; Biosight: Other: Data monitoring committee. Atallah: Novartis: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Research Funding; BMS: Honoraria, Speakers Bureau; Takeda: Consultancy, Research Funding; Abbvie: Consultancy, Speakers Bureau; Amgen: Consultancy.
Financial Toxicity and Associated Patient-Reported Quality of Life in Plasma Cell Disorders
Schmidt, Walker M. , Warsame, Rahma , Dueck, Amylou C. , Dispenzieri, Angela

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 4012-4012

10.1182/blood-2021-153271 Get It

Abstract Background: Advances in supportive care and novel therapies have driven improved outcomes for patients with Multiple myeloma (MM) and Light Chain Amyloidosis (AL). Unfortunately, this progress demands a heavy toll - higher patient costs. Financial toxicity (FT) is the adverse impact of cancer on a patient's financial well-being, contributing to increased distress, lower medication compliance, and even reduced survival. We aimed to evaluate MM and AL patients for financial toxicity over time to better understand its impact on various quality of life (QOL) domains. Methods: Adult patients with MM or AL that receive care at Mayo Clinic, Rochester MN, were recruited for a prospective study between December 2019 and March 2021. FT was measured using the validated COmprehensive Score for financial Toxicity (COST) questionnaire at the time of enrollment, 3 months, and 6 months follow-up. COST scores range from 0-44, with higher scores indicating lower FT. We defined patients with a COST score of ≤ 23 as having substantial FT. Domains of QOL were assessed via the Patient Reported Outcome Measurement Information System (PROMIS)-29 survey. Patient demographics and clinical information were abstracted from the electronic medical record. Statistical analysis included a comparison of COST scores among groups through Wilcoxon rank-sum, Kruskal-Wallis, and Jonckheere-Terpestra tests for binary, unordered, and ordered categorical variables, respectively. Results: One hundred and sixteen patients (96 MM, 83%; AL 20, 17%) enrolled in this study. The cohort is characterized as follows: 49% age 65+ (51% age 35-64), 54% male, 93% White, 4.3% Black, 3.5% Hispanic, 44% with incomes > USD 75k/yr (26% < USD 50k/yr), 77% with at least some college education (32% graduate or doctoral degree), 52% insured through Medicare (4.3% through Medicaid), 36% employed (53% retired), and 71% married (16% divorced). Forty-three percent of patients enrolled in the study were newly diagnosed (56% relapsed), and 72% had received an autologous stem cell transplant. Baseline mean COST score was25.9 (N=116; SD 10.2), with 37% reporting FT. A total of 101 patients (85 MM; 16 AL) completed a baseline and either 3- or 6-month COST survey. Thirty-eight of these patients (38%) reported FT at the time of enrollment. Among those reporting baseline FT, 71% continued to report FT at 3 or 6 months; 29% showed reduced FT. Of the 62% of patients who reported low FT at baseline, 78% showed continued low FT at 3 or 6 months; 22% showed increased FT. Results of longitudinal follow-up are outlined in Figure 1. FT was significantly associated with increased anxiety, depression, and pain intensity domains on the PROMIS-29. Substantial FT was associated with: women, Medicaid as primary insurance, and being divorced. FT was also greater in unemployed/disabled vs retired individuals. Conversely, low FT was associated with: males, earning > USD 75k/yr, Medicare as primary insurance, having at least some college education, being retired, and traveling 300+ miles for care. Financial toxicity did not differ significantly by age, race, ethnicity, disease status (newly diagnosed vs relapsed), or transplant status. Discussion : Financial toxicity was present in more than one-third of AL and MM patients in this high-earning and well-educated cohort. Financial toxicity was associated with increased anxiety, depression, and pain intensity, contributing to lower patient quality of life. Longitudinal follow-up has shown financial toxicity to be dynamic, necessitating routine evaluation of patient financial burdens. Future work will focus on automating FT assessment with incorporation into routine care and developing care processes to support patients. Figure 1 Figure 1. Disclosures Dispenzieri: Alnylam: Research Funding; Takeda: Research Funding; Pfizer: Research Funding; Oncopeptides: Consultancy; Sorrento Therapeutics: Consultancy; Janssen: Consultancy, Research Funding.
Preventiometer, a Novel Wellness Assessment Device, Used With Healthy Volunteers: A Phase 2 Study
Nanda, S. , Chon, Tony Y. , Mahapatra, Saswati , Lindeen, Stephanie A. , Krüger, Markus , Schierwater, Bernd , Wahner‐Roedler, Dietlind L. , Bauer, Brent A. , Nanda, Sanjeev , Schmidt, Carsten O, Wahner-Roedler, Dietlind L , Mahapatra, Saswati , Fischer, Karen M. , Schmidt, Carsten Oliver

Mayo Clinic

Global Advances in Health and Medicine | November 19, 2021 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/21649561211045016 | PMID 34840917 Get It

Background We previously reported on a pilot study to assess the incorporation of a novel wellness assessment device, the Preventiometer (iPEx5 GmbH, Greifswald, Germany), into an academic medical practice. The present follow-up study expands on those data and evaluates the acceptability of the assessment process in a larger sample population. Objective The aim of this study was to evaluate participant satisfaction with the Preventiometer wellness assessment. Methods A total of 60 healthy volunteers participated. Each participant underwent a comprehensive wellness assessment with the Preventiometer and received data from more than 30 diagnostic tests. A 32-question survey (with a numeric rating scale from 0 to 10) was used to rate the wellness assessment tests and participants’ impressions of the wellness assessment. Results Each assessment had a significantly higher rating than 7 ( P < .001), and the majority of participants agreed or strongly agreed that they were satisfied (98.3%), and they strongly agreed that they were engaged the entire time (93.2%), and liked the instant test results feature of the Preventiometer device (93.2%). Conclusion This study confirms findings from our previous pilot study regarding the feasibility of the Preventiometer as a wellness assessment tool. The study further demonstrated that 98% of participants were satisfied with the assessment and that all of them would recommend it to others.
NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT
Winklhofer, Sebastian , Lmalem, Hafida, Brandsma, Dieta , Compter, Annette , Dhermain, F., Glantz, Michael , Hempel, Johann, Jaeckle, Kurt A. , Kumthekar, Priya , O’Brien, Barbara , Postma, Tjeerd J., Schäfer, Niklas , Thust, Steffi, Tonn, Jörg‐Christian, Vogin, Guillaume , Wen, Patrick Y. , Rhun, Émilie Le , Devos, Patrick , Gállego Pérez-Larraya, Jaime , Castellano, Antonella , Franceschi, Enrico , Forsyth, Peter A , Furtner, Julia , Galldiks, Norbert , Gempt, Jens , Hattingen, Elke , Lukacova, Slávka , Minniti, Giuseppe , Roth, Patrick , Rudà, Roberta , Schmidt, Nils Ole , Smits, Marion , Snijders, Tom J , Thust, Steffi, Bent, Martin J. van den , Hoorn, Anouk van der , Preusser, Matthias , Wen, Patrick Yung , Bendszus, Martin , Weller, Michael

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi126-vi127

10.1093/neuonc/noab196.501 Get It

Abstract BACKGROUND Validation of the 2016 LANO MRI scorecard for leptomeningeal metastasis failed for multiple reasons. The objective of this joint EORTC Brain Tumor Group and RANO effort was to validate the feasibility of the revised MRI scorecard for assessing response in leptomeningeal metastasis. METHODS Coded paired cerebrospinal MRI of 20 patients with leptomeningeal metastases from solid cancers at baseline and follow-up after treatment and instructions for assessment were provided via the EORTC imaging platform. The kappa coefficient (K) was used to evaluate inter-observer pairwise agreement. Statistical analyses were performed using SAS V9.4 software (Cary, NC). The sponsor of the study was the University Hospital Zurich (2018-00192). RESULTS Thirty-five raters participated, including 9 neuroradiologists, 17 neurologists, 4 radiation oncologists, 3 neurosurgeons and 2 medical oncologists. Among leptomeningeal metastases-related items at baseline, the best median concordance was noted for hydrocephalus (K=0.63), and the worst median for spinal linear enhancing disease (K=0.46). The median concordance for overall response was moderate (K=0.44). Notably, the interobserver agreement for the presence of parenchymal brain metastases at baseline was minimal (K=0.29). Significant differences were observed when considering the specialty of the raters. Only 394 of 700 ratings (56%) were fully completed. Among 394 fully completed ratings, perfect concordance was noted in 293 ratings (74%) when comparing the overall response according to the guidelines provided in the scorecard and the overall response provided by the raters. The main discordances were noted for partial response according to the rater versus stable disease according to the guidelines (n=44), followed by progression according to the raters versus stable disease according to the guidelines (n=23). CONCLUSION Electronic case report forms with "blocking solutions" are probably required to enforce completeness and quality of scoring. These results confirm the necessity of central review and the need for training of MRI assessment in clinical trials.